DR. GIOVANNI ANNUNZIATO INFUSINO M.D.
Prescription History 1447416821
Internal Medicine - Pulmonary Disease in Crown Point, IN
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. GIOVANNI ANNUNZIATO INFUSINO M.D., an active Pulmonary Disease specialist practicing in Crown Point, IN. Our medical registry currently tracks 33 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,840 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 331 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other IN PrescribersVs. IN Avg |
|---|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 331 | $26.79 | ▲ More than typical |
About Albuterol Sulfate Hfa: Albuterol (also known as salbutamol) is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). Show more ▾ It is also used to prevent asthma brought on by exercise. It is a quick-relief drug. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. In 2024, this provider wrote 331 Medicare prescriptions for Albuterol Sulfate Hfa, about 4.3 times the volume of the typical Indiana prescriber of this medication (76.7). Medicare paid an average of $26.79 per fill, versus $24.93 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 401.4 30-Day Fills standardized to 30-day supplies 10,183 Days of Medication total across all patients in 2024 | |||
| Prednisone | 208 | $2.15▼ below IN avg | ▲ More than typical |
About Prednisone: Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Show more ▾ Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions. A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. In 2024, this provider wrote 208 Medicare prescriptions for Prednisone, about 4.3 times the volume of the typical Indiana prescriber of this medication (48.5). Medicare paid an average of $2.15 per fill, versus $3.47 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 220 30-Day Fills standardized to 30-day supplies 3,057 Days of Medication total across all patients in 2024 | |||
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 181 | $876.28▼ below IN avg | ▲ More than typical |
About Trelegy Ellipta: This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. In 2024, this provider wrote 181 Medicare prescriptions for Trelegy Ellipta, about 2.9 times the volume of the typical Indiana prescriber of this medication (62.1). Medicare paid an average of $876.28 per fill, versus $886.77 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 250 30-Day Fills standardized to 30-day supplies 7,500 Days of Medication total across all patients in 2024 | |||
| Montelukast Sodium | 103 | $11.74 | ▲ More than typical |
About Montelukast Sodium: Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). Show more ▾ It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways. A leukotriene D4 receptor antagonist. In 2024, this provider wrote 103 Medicare prescriptions for Montelukast Sodium, about 1.5 times the volume of the typical Indiana prescriber of this medication (67.5). Medicare paid an average of $11.74 per fill, versus $9.25 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 238.3 30-Day Fills standardized to 30-day supplies 7,150 Days of Medication total across all patients in 2024 | |||
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 98 | $746.80 | ▲ More than typical |
About Stiolto Respimat: This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems. In 2024, this provider wrote 98 Medicare prescriptions for Stiolto Respimat, about 3.2 times the volume of the typical Indiana prescriber of this medication (30.2). Medicare paid an average of $746.80 per fill, versus $660.59 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 156 30-Day Fills standardized to 30-day supplies 4,680 Days of Medication total across all patients in 2024 | |||
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 96 | $640.91 | ▲ More than typical |
About Anoro Ellipta: This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems. In 2024, this provider wrote 96 Medicare prescriptions for Anoro Ellipta, about 3.2 times the volume of the typical Indiana prescriber of this medication (30.1). Medicare paid an average of $640.91 per fill, versus $585.75 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 132 30-Day Fills standardized to 30-day supplies 3,960 Days of Medication total across all patients in 2024 | |||
| Breo ElliptaFluticasone/Vilanterol | 91 | $561.95 | ▲ More than typical |
About Breo Ellipta: This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). Show more ▾ This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. In 2024, this provider wrote 91 Medicare prescriptions for Breo Ellipta, about 2.7 times the volume of the typical Indiana prescriber of this medication (34.1). Medicare paid an average of $561.95 per fill, versus $538.67 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 131 30-Day Fills standardized to 30-day supplies 3,930 Days of Medication total across all patients in 2024 | |||
| Spiriva RespimatTiotropium Bromide | 54 | $643.93▼ below IN avg | ▲ More than typical |
About Spiriva Respimat: Tiotropium is used to treat lung diseases such as asthma and COPD (bronchitis, emphysema). Show more ▾ It must be used regularly to prevent wheezing and shortness of breath. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. In 2024, this provider wrote 54 Medicare prescriptions for Spiriva Respimat, about 1.7 times the volume of the typical Indiana prescriber of this medication (30.9). Medicare paid an average of $643.93 per fill, versus $720.74 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 68 30-Day Fills standardized to 30-day supplies 2,040 Days of Medication total across all patients in 2024 | |||
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $821.96 | ▲ More than typical |
About Breztri Aerosphere: This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma. In 2024, this provider wrote 53 Medicare prescriptions for Breztri Aerosphere, about 1.4 times the volume of the typical Indiana prescriber of this medication (38.9). Medicare paid an average of $821.96 per fill, versus $793.28 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 71 30-Day Fills standardized to 30-day supplies 2,130 Days of Medication total across all patients in 2024 | |||
| OfevNintedanib Esylate | 44 | $9,910.30▼ below IN avg | ▲ More than typical |
About Ofev: This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Show more ▾ Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease. In 2024, this provider wrote 44 Medicare prescriptions for Ofev, about 1.5 times the volume of the typical Indiana prescriber of this medication (29.3). Medicare paid an average of $9,910.30 per fill, versus $12,544.12 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 44 30-Day Fills standardized to 30-day supplies 1,320 Days of Medication total across all patients in 2024 | |||
| Incruse ElliptaUmeclidinium Bromide | 43 | $339.98▼ below IN avg | ▲ More than typical |
About Incruse Ellipta: Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). Show more ▾ It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. Muscarinic Antagonist. In 2024, this provider wrote 43 Medicare prescriptions for Incruse Ellipta, about 1.8 times the volume of the typical Indiana prescriber of this medication (24.2). Medicare paid an average of $339.98 per fill, versus $395.60 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 43 30-Day Fills standardized to 30-day supplies 1,290 Days of Medication total across all patients in 2024 | |||
| Ventolin HfaAlbuterol Sulfate | 40 | $90.18 | ▲ More than typical |
About Ventolin Hfa: Albuterol (also known as salbutamol) is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). Show more ▾ It is also used to prevent asthma brought on by exercise. It is a quick-relief drug. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. In 2024, this provider wrote 40 Medicare prescriptions for Ventolin Hfa, about 1.7 times the volume of the typical Indiana prescriber of this medication (23.9). Medicare paid an average of $90.18 per fill, versus $68.72 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 53.3 30-Day Fills standardized to 30-day supplies 1,372 Days of Medication total across all patients in 2024 | |||
| XolairOmalizumab | 39 | $4,515.88 | ▲ More than typical |
About Xolair: Omalizumab is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma that is due to year-round allergens. Show more ▾ Controlling symptoms of asthma helps you maintain your normal activities and cuts down on time lost from work or school. Omalizumab may also be used to treat certain growths in the nose (chronic rhinosinusitis with nasal polyps) or to treat hives from an unknown cause (chronic spontaneous urticaria-CSU). Omalizumab is also used in people with a certain type of food allergy (IgE-mediated food allergy) while continuing to avoid food allergens. It may help lower the risk of having serious allergic reactions. This medication must be used regularly to be effective. It does not work right away and should not be used as an emergency treatment for serious allergic reactions or to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, salbutamol) as prescribed. An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA. In 2024, this provider wrote 39 Medicare prescriptions for Xolair, about 1.3 times the volume of the typical Indiana prescriber of this medication (30.0). Medicare paid an average of $4,515.88 per fill, versus $3,474.33 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 39 30-Day Fills standardized to 30-day supplies 1,092 Days of Medication total across all patients in 2024 | |||
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 39 | $7.05▼ below IN avg | ▲ More than typical |
About Amoxicillin-Clavulanate Potass: Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. Show more ▾ It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. In 2024, this provider wrote 39 Medicare prescriptions for Amoxicillin-Clavulanate Potass, about 1.4 times the volume of the typical Indiana prescriber of this medication (27.2). Medicare paid an average of $7.05 per fill, versus $8.68 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 39 30-Day Fills standardized to 30-day supplies 298 Days of Medication total across all patients in 2024 | |||
| Arnuity ElliptaFluticasone Furoate | 38 | $265.29▼ below IN avg | ▲ More than typical |
About Arnuity Ellipta: Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Show more ▾ Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS. In 2024, this provider wrote 38 Medicare prescriptions for Arnuity Ellipta, about 1.8 times the volume of the typical Indiana prescriber of this medication (21.5). Medicare paid an average of $265.29 per fill, versus $297.90 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 40 30-Day Fills standardized to 30-day supplies 1,200 Days of Medication total across all patients in 2024 | |||
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $94.07▼ below IN avg | ▲ More than typical |
About Wixela Inhub: This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. In 2024, this provider wrote 35 Medicare prescriptions for Wixela Inhub, about 1.7 times the volume of the typical Indiana prescriber of this medication (20). Medicare paid an average of $94.07 per fill, versus $123.39 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 41 30-Day Fills standardized to 30-day supplies 1,230 Days of Medication total across all patients in 2024 | |||
| SymbicortBudesonide/Formoterol Fumarate | 35 | $342.96 | ▲ More than typical |
About Symbicort: This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section. A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. In 2024, this provider wrote 35 Medicare prescriptions for Symbicort, about 1.4 times the volume of the typical Indiana prescriber of this medication (24.6). Medicare paid an average of $342.96 per fill, versus $330.07 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 53 30-Day Fills standardized to 30-day supplies 1,590 Days of Medication total across all patients in 2024 | |||
| Azithromycin | 35 | $3.08▼ below IN avg | ≈ Typical |
About Azithromycin: Azithromycin is used to treat a wide variety of bacterial infections. Show more ▾ It is a macrolide-type antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness. A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. In 2024, this provider wrote 35 Medicare prescriptions for Azithromycin, about the same volume as the typical Indiana prescriber of this medication (33.2). Medicare paid an average of $3.08 per fill, versus $4.58 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 35 30-Day Fills standardized to 30-day supplies 175 Days of Medication total across all patients in 2024 | |||
| Roflumilast | 33 | $95.55 | ≈ Typical |
About Roflumilast: Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). Show more ▾ It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. In 2024, this provider wrote 33 Medicare prescriptions for Roflumilast, about 90% of the volume of the typical Indiana prescriber of this medication (36.7). Medicare paid an average of $95.55 per fill, versus $73.87 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 63 30-Day Fills standardized to 30-day supplies 1,890 Days of Medication total across all patients in 2024 | |||
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 31 | $112.06▼ below IN avg | ≈ Typical |
About Fluticasone-Salmeterol: This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. A drug combination of fluticasone and salmeterol that is used as an inhaler formulation to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE. In 2024, this provider wrote 31 Medicare prescriptions for Fluticasone-Salmeterol, about the same volume as the typical Indiana prescriber of this medication (28.3). Medicare paid an average of $112.06 per fill, versus $126.73 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 54 30-Day Fills standardized to 30-day supplies 1,620 Days of Medication total across all patients in 2024 | |||
| CefuroximeCefuroxime Axetil | 30 | $16.53▼ below IN avg | ≈ Typical |
About Cefuroxime: Cefuroxime is used to treat a wide variety of bacterial infections. Show more ▾ This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. In 2024, this provider wrote 30 Medicare prescriptions for Cefuroxime, about the same volume as the typical Indiana prescriber of this medication (31.5). Medicare paid an average of $16.53 per fill, versus $18.84 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 30 30-Day Fills standardized to 30-day supplies 228 Days of Medication total across all patients in 2024 | |||
| Doxycycline Hyclate | 25 | $6.26▼ below IN avg | ≈ Typical |
About Doxycycline Hyclate: This medication is used to treat a wide variety of bacterial infections, including those that cause acne. Show more ▾ This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. A synthetic tetracycline derivative with similar antimicrobial activity. In 2024, this provider wrote 25 Medicare prescriptions for Doxycycline Hyclate, about 77% of the volume of the typical Indiana prescriber of this medication (32.4). Medicare paid an average of $6.26 per fill, versus $12.01 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 25 30-Day Fills standardized to 30-day supplies 172 Days of Medication total across all patients in 2024 | |||
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $568.50 | ≈ Typical |
About Bevespi Aerosphere: This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 2 medications: glycopyrrolate and formoterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. Glycopyrrolate/formoterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as formoterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems. In 2024, this provider wrote 20 Medicare prescriptions for Bevespi Aerosphere, about 1.2 times the volume of the typical Indiana prescriber of this medication (16.3). Medicare paid an average of $568.50 per fill, versus $495.75 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 28 30-Day Fills standardized to 30-day supplies 840 Days of Medication total across all patients in 2024 | |||
| Fluticasone Propionate | 19 | $21.54 | ▼ Less than typical |
About Fluticasone Propionate: Fluticasone is used to relieve seasonal and year-round allergic and non-allergic nasal symptoms, such as stuffy/runny nose, itching, and sneezing. Show more ▾ It can also help relieve allergy eye symptoms such as itchy, watery eyes. This medication belongs to a class of drugs known as corticosteroids. It works in your nose to block the effects of substances that cause allergies (such as pollen, pet dander, dust mites, mold) and to reduce swelling. A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS. In 2024, this provider wrote 19 Medicare prescriptions for Fluticasone Propionate, about a third of the volume of the typical Indiana prescriber of this medication (48.9). Medicare paid an average of $21.54 per fill, versus $14.80 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 44 30-Day Fills standardized to 30-day supplies 1,320 Days of Medication total across all patients in 2024 | |||
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $135.61▼ below IN avg | ≈ Typical |
About Budesonide-Formoterol Fumarate: This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Show more ▾ It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section. In 2024, this provider wrote 18 Medicare prescriptions for Budesonide-Formoterol Fumarate, about 78% of the volume of the typical Indiana prescriber of this medication (23.1). Medicare paid an average of $135.61 per fill, versus $170.12 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 18 30-Day Fills standardized to 30-day supplies 540 Days of Medication total across all patients in 2024 | |||
| Spiriva HandihalerTiotropium Bromide | 15 | $1,426.50 | ≈ Typical |
About Spiriva Handihaler: Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). Show more ▾ It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE. In 2024, this provider wrote 15 Medicare prescriptions for Spiriva Handihaler, about 81% of the volume of the typical Indiana prescriber of this medication (18.6). Medicare paid an average of $1,426.50 per fill, versus $752.58 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 43 30-Day Fills standardized to 30-day supplies 1,290 Days of Medication total across all patients in 2024 | |||
| Levofloxacin | 15 | $2.92▼ below IN avg | ▼ Less than typical |
About Levofloxacin: Levofloxacin is used to treat a variety of bacterial infections. Show more ▾ This medication belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. The L-isomer of Ofloxacin. In 2024, this provider wrote 15 Medicare prescriptions for Levofloxacin, about half the volume of the typical Indiana prescriber of this medication (25.8). Medicare paid an average of $2.92 per fill, versus $5.96 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 15 30-Day Fills standardized to 30-day supplies 103 Days of Medication total across all patients in 2024 | |||
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $8,971.95▼ below IN avg | ≈ Typical |
About Prolastin C: This medication is used to treat lung problems (emphysema) caused by a certain inherited disease (alpha-1-proteinase inhibitor deficiency). Show more ▾ In people with this condition, lung damage is caused by elastase, a natural substance that the body needs to kill bacteria in the lungs. Normally, a protein (alpha-1-proteinase inhibitor) stops elastase from working when it is no longer needed. However, in people who do not make enough of this protein, elastase does not stop working and damages the lungs. This medication replaces the missing alpha-1-proteinase inhibitor and helps to prevent further lung damage. Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES. In 2024, this provider wrote 13 Medicare prescriptions for Prolastin C, about 78% of the volume of the typical Indiana prescriber of this medication (16.6). Medicare paid an average of $8,971.95 per fill, versus $11,446.08 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 13 30-Day Fills standardized to 30-day supplies 364 Days of Medication total across all patients in 2024 | |||
| OpsumitMacitentan | 12 | $12,820.12 | ▼ Less than typical |
About Opsumit: Macitentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). Show more ▾ This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1). This medication blocks the effects of endothelin-1, which helps decrease the blood pressure in the lungs, and reduces the risk of worsening of symptoms and hospital stays due to the disease. In 2024, this provider wrote 12 Medicare prescriptions for Opsumit, about a quarter of the volume of the typical Indiana prescriber of this medication (50). Medicare paid an average of $12,820.12 per fill, versus $12,689.72 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $352.73 | ≈ Typical |
About Fluticasone Propionate Hfa: Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Show more ▾ It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS. In 2024, this provider wrote 12 Medicare prescriptions for Fluticasone Propionate Hfa, about 81% of the volume of the typical Indiana prescriber of this medication (14.9). Medicare paid an average of $352.73 per fill, versus $304.03 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2024 | |||
| Dupixent PenDupilumab | 12 | $3,898.28▼ below IN avg | ▼ Less than typical |
About Dupixent Pen: This medication is used to treat certain skin conditions (eczema, prurigo nodularis) and a certain esophagus problem (eosinophilic esophagitis). Show more ▾ It is also used along with other medications to help control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD). In addition, dupilumab may be used to reduce symptoms caused by nasal polyps and the long-term swelling of the sinuses and nasal passage (chronic rhinosinusitis with nasal polyposis). Dupilumab belongs to a class of drugs known as monoclonal antibodies. It works by blocking certain natural proteins in your body (interleukin-4 and interleukin-13) that may cause inflammation and swelling. This medication should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. Targets the alpha subunit of interleukin-4 receptor. In 2024, this provider wrote 12 Medicare prescriptions for Dupixent Pen, about a third of the volume of the typical Indiana prescriber of this medication (29.2). Medicare paid an average of $3,898.28 per fill, versus $3,956.24 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 12 30-Day Fills standardized to 30-day supplies 322 Days of Medication total across all patients in 2024 | |||
| EliquisApixaban | 11 | $578.06▼ below IN avg | ▼ Less than typical |
About Eliquis: Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. Show more ▾ With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood. An antithrombotic agent. In 2024, this provider wrote 11 Medicare prescriptions for Eliquis, about 11% of the volume of the typical Indiana prescriber of this medication (102.9). Medicare paid an average of $578.06 per fill, versus $840.97 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 11 30-Day Fills standardized to 30-day supplies 330 Days of Medication total across all patients in 2024 | |||
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 11 | $49.23▼ below IN avg | ▼ Less than typical |
About Levalbuterol Tartrate Hfa: Levalbuterol is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). Show more ▾ It is a quick-relief drug. Levalbuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. This drug is not approved for use in children younger than 4 years due to increased risk of side effects (such as unusual fast breathing, worsening asthma). Ask your doctor or pharmacist for details. The R-isomer of albuterol. In 2024, this provider wrote 11 Medicare prescriptions for Levalbuterol Tartrate Hfa, about half the volume of the typical Indiana prescriber of this medication (18.4). Medicare paid an average of $49.23 per fill, versus $53.21 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average IN prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the IN average for this medication. 13 30-Day Fills standardized to 30-day supplies 375 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for DR. GIOVANNI ANNUNZIATO INFUSINO M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Pulmonary Disease prescribing approach at this Crown Point, IN practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among IN prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
